Gabapentin Lawsuit 2026: Philadelphia Just Created a Mass Tort Program for Dementia Claims — Who Qualifies?
On October 8, 2026, a Philadelphia court created a coordinated mass tort program for lawsuits linking the nerve-pain drugs gabapentin and pregabalin to dementia and cognitive decline. Twenty-eight cases entered within days. The claims allege the manufacturers failed to warn about neurocognitive risks — and this litigation is just beginning.
Key facts
- October 8, 2026: a case management order established Philadelphia's mass tort program for gabapentin and pregabalin neurocognitive-injury claims.
- 28 cases were in the program as of October 13, 2026, covering both drugs.
- Named defendants include Pfizer, Greenstone, Pharmacia & Upjohn, Pharmacia, and Viatris.
- A 2025 observational study in Regional Anesthesia & Pain Medicine linked repeated gabapentin prescriptions to higher dementia and mild cognitive impairment rates — an association, not proof of causation.
- No settlements or verdicts have been announced; the litigation is in its earliest phase.
What the Philadelphia program actually does
A mass tort program is a coordinated state-court proceeding: each lawsuit keeps its own plaintiff, injuries, and damages, but all share pretrial work — document discovery, expert preparation, scheduling — before one court instead of scattering across dozens of courtrooms. Philadelphia's Complex Litigation Center has hosted some of the country's largest pharmaceutical programs this way.
The October 8 order gives the gabapentin litigation its first real home. The Legal Intelligencer reported the program's formation on October 15, 2026: the complaints allege early-onset dementia and neurocognitive decline from gabapentinoids — drugs that suppress neurotransmitter activity — and accuse the manufacturers of failing to warn patients and prescribing doctors. For potential plaintiffs, coordination means one set of rules, one discovery record, and a case that moves instead of idling.
The study behind the lawsuits
The foundation is a 2025 study of chronic low back pain patients in Regional Anesthesia & Pain Medicine. Patients with repeated gabapentin prescriptions were diagnosed with dementia and mild cognitive impairment at higher rates than comparable patients without the drug. The signal was strongest in non-elderly adults — sharpest in ages 35 to 49 — and grew with the number of prescriptions.
The study has a hard limit: it was observational, so it found an association, not proof of causation. A 2024 study of older adults with existing cognitive impairment found no significant association over one to two years — though it did report more falls. The defense will lean on that mixed record; plaintiffs will answer with experts explaining why the 2025 results matter most for younger patients, chronic-pain patients, and those with repeated prescriptions. Expect the science, not the sympathy, to decide which claims survive.
What the lawsuits allege
The core claim is failure to warn: the manufacturers knew or should have known about potential long-term cognitive risks and never adequately warned doctors or patients. The complaints name Pfizer, Greenstone, Pharmacia & Upjohn, Pharmacia, and Viatris — the companies behind brand-name Neurontin (gabapentin) and Lyrica (pregabalin) — and center discovery on a pointed question: what did these companies know about an early-onset dementia risk as far back as the early 1990s?
The cases also highlight how the drugs are actually used. Gabapentin and pregabalin are widely prescribed "off-label" — prescribed for conditions the FDA has not approved them to treat, such as chronic back pain, fibromyalgia, anxiety, and insomnia. Millions took them for years: exactly the exposure pattern the 2025 study flagged. Drug mass torts follow a familiar arc — coordinated discovery, dueling experts, bellwether trials — as seen in the GLP-1 gastrointestinal litigation (see our Ozempic Lawsuit Update October 2026).
Who qualifies for a case review
Firms are reviewing claims involving long-term or repeated gabapentin or pregabalin use followed by dementia, mild cognitive impairment, early-onset dementia, or serious documented memory loss. The strongest files share a pattern: years of prescriptions, a clear cognitive diagnosis afterward, and medical records connecting the two.
Intake turns on four things: prescription history, diagnosis and treatment records, your state's law, and whether you took the brand-name drug or a generic — firms evaluate that distinction because the legal theories differ. Your pharmacy records answer the brand question in minutes. Pharmaceutical mass torts from Depo-Provera to Suboxone have all turned on the same documentation.
Deadlines: why the clock matters now
Every state sets its own statute of limitations — the filing deadline — and many apply a "discovery rule": the clock starts when you reasonably learned, or should have learned, that the drug may have caused the injury. For a litigation this new, that rule matters enormously. Families who connected the dots only after the 2025 study or the October 2026 program may have more time than they assume; families who wait may have less.
There is a practical reason to move early. The program is in its infancy — 28 cases, no bellwether schedule, no settlement framework — and early filers get reviewed while pharmacies, physicians' files, and memories are freshest. Waiting for a settlement announcement before calling a lawyer is the most common way strong claims die quietly.
What filing looks like
This is not a class action. In a class action, one settlement is divided among all members; in a mass tort, each person has an individual case with individually evaluated damages — a structure that favors people with serious, well-documented injuries.
Getting in costs nothing upfront. Firms work on contingency — paid a percentage only if you recover — and case reviews are free. The intake work is theirs: prescription history, records, diagnosis, state law, brand versus generic. Yours is to gather what you have and make the call.
What happens next
Watch three milestones: discovery into internal company documents — what the manufacturers knew and when; the expert battle over general causation; and the program's growth, since 28 cases is a beginning and mass torts are judged by trajectory. No settlement talks, trial dates, or payouts exist yet — anyone quoting you a figure today is guessing. For plain-language walkthroughs of how mass tort programs work, the Problem Solved channel explains complex litigation in everyday terms. If this touches your family, the honest move is a free case review now, while the program is young and the evidence is fresh.
Who Benefits From This — and Who Does Not
Long-term gabapentin or pregabalin users later diagnosed with cognitive decline. The strongest files share a pattern the article describes: years of repeated prescriptions, followed by a diagnosis of dementia, mild cognitive impairment, or early-onset dementia, with medical records connecting the two — gather your prescription history and diagnosis records before a free case review.
Families of patients in the 35-to-49 signal group. The 2025 study's signal was sharpest in non-elderly adults, especially ages 35 to 49, and grew with the number of prescriptions — if that pattern matches your family member's history, preserve pharmacy records showing the prescription count over time.
Patients unsure whether brand or generic matters. Firms evaluate that distinction because the legal theories differ, so bring the exact product history — brand-name Neurontin or Lyrica versus a generic — to the review rather than assuming one answer fits all.
Who does not benefit. Short-term users with no cognitive diagnosis have no claim pattern to review, and no one should treat the 2025 study as proof: it was observational, finding an association rather than causation, while a 2024 study of older adults found no significant association over one to two years. No settlement or verdict exists yet, so anyone seeking a payout now will wait. For how another drug safety issue is unfolding, see our telmisartan and amlodipine superpotent recall update.
Frequently asked questions
Is there a gabapentin settlement yet?
No. As of October 2026, no settlements or verdicts have been announced. The Philadelphia mass tort program was created on October 8, 2026, and cases are in the earliest pretrial phase.
Can gabapentin cause dementia?
Researchers have not established causation. A 2025 observational study found higher dementia and mild cognitive impairment rates among patients with repeated gabapentin prescriptions — an association, not proof. The lawsuits pair that association with failure-to-warn allegations.
Is this a class action?
No. It is a mass tort program: individual lawsuits coordinated for pretrial work, each plaintiff's case and damages evaluated separately — not one shared settlement.
Do I qualify if I took generic gabapentin?
Possibly. Firms review brand-name versus generic use during intake because the legal theories can differ, and the answer varies by state. Your pharmacy records show which version you took.
What does it cost to have my case reviewed?
Nothing upfront. Firms offer free case reviews and work on contingency — they collect a fee only if you recover compensation.
Who is most likely to benefit from a gabapentin case review?
People with long-term or repeated gabapentin or pregabalin use followed by dementia, mild cognitive impairment, or serious documented memory loss — especially where prescription records and a clear cognitive diagnosis connect the two — since firms review exactly that pattern in the 28 cases now in Philadelphia's program.
This article is general information about an ongoing litigation, not legal or medical advice. Do not stop or change any medication without speaking to your doctor. For questions about your legal rights, consult a qualified attorney in your state.